256 related articles for article (PubMed ID: 18952846)
1. Role of TGF-beta in proliferative vitreoretinal diseases and ROCK as a therapeutic target.
Kita T; Hata Y; Arita R; Kawahara S; Miura M; Nakao S; Mochizuki Y; Enaida H; Goto Y; Shimokawa H; Hafezi-Moghadam A; Ishibashi T
Proc Natl Acad Sci U S A; 2008 Nov; 105(45):17504-9. PubMed ID: 18952846
[TBL] [Abstract][Full Text] [Related]
2. [Molecular mechanisms of preretinal membrane contraction in proliferative vitreoretinal diseases and ROCK as a therapeutic target].
Kita T
Nippon Ganka Gakkai Zasshi; 2010 Nov; 114(11):927-34. PubMed ID: 21141072
[TBL] [Abstract][Full Text] [Related]
3. Critical role of the Rho-kinase pathway in TGF-beta2-dependent collagen gel contraction by retinal pigment epithelial cells.
Miura M; Hata Y; Hirayama K; Kita T; Noda Y; Fujisawa K; Shimokawa H; Ishibashi T
Exp Eye Res; 2006 May; 82(5):849-59. PubMed ID: 16310190
[TBL] [Abstract][Full Text] [Related]
4. Potent inhibition of cicatricial contraction in proliferative vitreoretinal diseases by statins.
Kawahara S; Hata Y; Kita T; Arita R; Miura M; Nakao S; Mochizuki Y; Enaida H; Kagimoto T; Goto Y; Hafezi-Moghadam A; Ishibashi T
Diabetes; 2008 Oct; 57(10):2784-93. PubMed ID: 18599521
[TBL] [Abstract][Full Text] [Related]
5. Glucosamine inhibits epithelial-to-mesenchymal transition and migration of retinal pigment epithelium cells in culture and morphologic changes in a mouse model of proliferative vitreoretinopathy.
Liang CM; Tai MC; Chang YH; Chen YH; Chen CL; Lu DW; Chen JT
Acta Ophthalmol; 2011 Sep; 89(6):e505-14. PubMed ID: 21457483
[TBL] [Abstract][Full Text] [Related]
6. Inhibition by female sex hormones of collagen gel contraction mediated by retinal pigment epithelial cells.
Kimura K; Orita T; Fujitsu Y; Liu Y; Wakuta M; Morishige N; Suzuki K; Sonoda KH
Invest Ophthalmol Vis Sci; 2014 Apr; 55(4):2621-30. PubMed ID: 24609629
[TBL] [Abstract][Full Text] [Related]
7. The involvement of the rho-kinase pathway and its regulation in cytokine-induced collagen gel contraction by hyalocytes.
Hirayama K; Hata Y; Noda Y; Miura M; Yamanaka I; Shimokawa H; Ishibashi T
Invest Ophthalmol Vis Sci; 2004 Nov; 45(11):3896-903. PubMed ID: 15505034
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor-beta2 and connective tissue growth factor in proliferative vitreoretinal diseases: possible involvement of hyalocytes and therapeutic potential of Rho kinase inhibitor.
Kita T; Hata Y; Kano K; Miura M; Nakao S; Noda Y; Shimokawa H; Ishibashi T
Diabetes; 2007 Jan; 56(1):231-8. PubMed ID: 17192487
[TBL] [Abstract][Full Text] [Related]
9. The Rho kinase inhibitor, fasudil, ameliorates diabetes-induced cardiac dysfunction by improving calcium clearance and actin remodeling.
Lai D; Gao J; Bi X; He H; Shi X; Weng S; Chen Y; Yang Y; Ye Y; Fu G
J Mol Med (Berl); 2017 Feb; 95(2):155-165. PubMed ID: 27576917
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis in proliferative vitreoretinal disorders: possible involvement of TGF-beta-induced RPE cell apoptosis.
Esser P; Heimann K; Bartz-schmidt KU; Fontana A; Schraermeyer U; Thumann G; Weller M
Exp Eye Res; 1997 Sep; 65(3):365-78. PubMed ID: 9299173
[TBL] [Abstract][Full Text] [Related]
11. TGF-beta1, TGF-beta receptor II and ED-A fibronectin expression in myofibroblast of vitreoretinopathy.
Bochaton-Piallat ML; Kapetanios AD; Donati G; Redard M; Gabbiani G; Pournaras CJ
Invest Ophthalmol Vis Sci; 2000 Jul; 41(8):2336-42. PubMed ID: 10892881
[TBL] [Abstract][Full Text] [Related]
12. [Periostin in the Pathogenesis of Proliferative Vitreoretinopathy].
Ishikawa K
Nippon Ganka Gakkai Zasshi; 2015 Nov; 119(11):772-80. PubMed ID: 26685481
[TBL] [Abstract][Full Text] [Related]
13. Periostin promotes the generation of fibrous membranes in proliferative vitreoretinopathy.
Ishikawa K; Yoshida S; Nakao S; Nakama T; Kita T; Asato R; Sassa Y; Arita R; Miyazaki M; Enaida H; Oshima Y; Murakami N; Niiro H; Ono J; Matsuda A; Goto Y; Akashi K; Izuhara K; Kudo A; Kono T; Hafezi-Moghadam A; Ishibashi T
FASEB J; 2014 Jan; 28(1):131-42. PubMed ID: 24022401
[TBL] [Abstract][Full Text] [Related]
14. A Rho kinase inhibitor (Fasudil) suppresses TGF-β mediated autophagy in urethra fibroblasts to attenuate traumatic urethral stricture (TUS) through re-activating Akt/mTOR pathway: An in vitro study.
Feng H; Huang X; Fu W; Dong X; Yang F; Li L; Chu L
Life Sci; 2021 Feb; 267():118960. PubMed ID: 33373654
[TBL] [Abstract][Full Text] [Related]
15. Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage.
Arita R; Hata Y; Nakao S; Kita T; Miura M; Kawahara S; Zandi S; Almulki L; Tayyari F; Shimokawa H; Hafezi-Moghadam A; Ishibashi T
Diabetes; 2009 Jan; 58(1):215-26. PubMed ID: 18840783
[TBL] [Abstract][Full Text] [Related]
16. [Preventive strategy for the treatment of diabetic vitreoretinopathy].
Hata Y
Nippon Ganka Gakkai Zasshi; 2009 Mar; 113(3):379-401; discussion 402. PubMed ID: 19348184
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of DNA Methylation and Methyl-CpG-Binding Protein 2 Suppresses RPE Transdifferentiation: Relevance to Proliferative Vitreoretinopathy.
He S; Barron E; Ishikawa K; Nazari Khanamiri H; Spee C; Zhou P; Kase S; Wang Z; Dustin LD; Hinton DR
Invest Ophthalmol Vis Sci; 2015 Aug; 56(9):5579-89. PubMed ID: 26305530
[TBL] [Abstract][Full Text] [Related]
18. LIMK1 depletion enhances fasudil-dependent inhibition of urethral fibroblast proliferation and migration.
Liang YC; Li XD; Wu YP; Ke ZB; Liu ZQ; Chen SH; Wei Y; Zheng QS; Xue XY; Xu N
J Cell Biochem; 2019 Aug; 120(8):12977-12988. PubMed ID: 30861189
[TBL] [Abstract][Full Text] [Related]
19. BMP7 antagonizes proliferative vitreoretinopathy through retinal pigment epithelial fibrosis in vivo and in vitro.
Yao H; Ge T; Zhang Y; Li M; Yang S; Li H; Wang F
FASEB J; 2019 Mar; 33(3):3212-3224. PubMed ID: 30383450
[TBL] [Abstract][Full Text] [Related]
20. Rho kinase inhibitors block activation of pancreatic stellate cells.
Masamune A; Kikuta K; Satoh M; Satoh K; Shimosegawa T
Br J Pharmacol; 2003 Dec; 140(7):1292-302. PubMed ID: 14581180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]